EMA Advises Against Renewal of Authorization for Translarna in Duchenne Muscular Dystrophy Treatment.

In the medicines development arena, and to ensure timely access to the latest therapies, particularly for patients with rare diseases, regulatory bodies frequently grant conditional approvals. This allows immediate availability of the new drug to patients, even with limited clinical documentation. However, the applicant is required to submit additional clinical data on safety and efficacy. Here, we discuss a scenario where the subsequent data did not substantiate the marketing authorization, leading to the withdrawal of the new drug from the market.

The European Medicines Agency’s human medicines committee (CHMP) has recommended against renewing the marketing authorization for Translarna (ataluren), a drug designed to treat Duchenne muscular dystrophy in patients who can walk and whose condition is caused by a ‘nonsense mutation’ in the dystrophin gene. This decision comes after a thorough reassessment of the medicine’s benefits and risks during the renewal process, which included findings from a new study that did not confirm Translarna’s effectiveness.

Translarna had initially received conditional marketing authorization in July 2014 due to its potential to address an unmet medical need for a severe disease. Conditional authorization allows a medicine to be approved with less comprehensive data than typically required, provided that the benefits of early availability outweigh potential risks while awaiting further evidence. Medicines with conditional authorization are subject to specific post-approval obligations aimed at generating comprehensive data.¹

Read more here.

References

1. Ema. (2023, October 5). EMA recommends non-renewal of authorisation Duchenne muscular dystrophy medicine Translarna – European Medicines Agency. European Medicines Agency. https://www.ema.europa.eu/en/news/ema-recommends-non-renewal-authorisation-duchenne-muscular-dystrophy-medicine-translarna

Disclaimers

• The material in these reviews is from various public open-access sources, meant for educational and informational purposes only
• Any personal opinions expressed are those of only the author(s) and are not intended to represent the position of any organization(s)
• No official support by any organization(s) has been provided or should be inferred

Recommended Reads

• Closing the vaccine-coverage gap for uninsured adults
• COVID-19 and Cooler Temps: What’s in the Forecast
• A Closer Look at the Number of SARS-CoV-2 Infections
• The Ethics Behind Vaccine Trials, Policies, and Access
• National Medical Products Administration (NMPA) issues progressive guidance in China